Explanipedia

Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease Open

J. Bradley Layton, Ryan Ziemiecki, Catherine B. Johannes, Manel Pladevall, Anam Khan , et al. · 2025

Understanding the incidence of kidney failure and cardiovascular outcomes in people receiving antidiabetic medications with cardiorenal protective effects is important for future studies aiming to compare the incidence of kidney and cardio…

Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study Open

Manel Pladevall, Ryan Ziemiecki, Catherine B. Johannes, Anam Khan, Daniel Mines , et al. · 2025

Change in Urine Albumin-Creatinine Ratio and Occurrence of Hyperkalemia in Patients Initiating Finerenone in the USA: A Cohort Study from the FOUNTAIN Platform Open

Csaba P. Kövesdy, Natalie Ebert, David Vizcaya, Michael D. Walsh, Mikhail Kosiborod , et al. · 2025

Introduction: In 2021, finerenone – a novel, selective nonsteroidal mineralocorticoid receptor antagonist – was approved in the USA to treat adults with chronic kidney disease (CKD) and type 2 diabetes (T2D). This study aimed to describe c…

Finerenone Efficacy in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Anemia in FIDELITY Open

A.K. Singh, Glen James, Stefan D. Anker, Bertram Pitt, Peter Rossing , et al. · 2025

Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study Open

Catherine B. Johannes, Ryan Ziemiecki, Manel Pladevall, Natalie Ebert, Csaba P. Kövesdy , et al. · 2024

Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes Open

Gerasimos Filippatos, Stefan D. Anker, George L. Bakris, Peter Rossing, Luís M. Ruilope , et al. · 2024

Aims Left ventricular hypertrophy (LVH) has been associated with an increased risk of cardiovascular (CV) disease and linked to increased morbidity and mortality. In patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), hyp…

Early Clinical Experience of Finerenone in People with Chronic Kidney Disease and Type 2 Diabetes in Japan—A Multi-Cohort Study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) Platform Open

Atsuhisa Sato, Daloha Rodríguez-Molina, Kanae Yoshikawa‐Ryan, Satoshi Yamashita, Suguru Okami , et al. · 2024

Background: In the phase 3 clinical trials FIGARO-DKD and FIDELIO-DKD, finerenone reduced the risk of cardiovascular and kidney events among people with chronic kidney disease (CKD) and type 2 diabetes (T2D). Evidence regarding finerenone …

#2022 Clinical outcomes in US patients initiating finerenone – a report from the FOUNTAIN platform Open

Nikolaus G. Oberprieler, Csaba P. Kövesdy, J. Bradley Layton, Bishnu Thapa, Gary C. Curhan , et al. · 2024

Background and Aims Evidence from clinical trials demonstrates that finerenone reduces the risk of cardiovascular and renal complications among patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). What is lacking is the ev…

#2546 CKD-PC risk model for CKD progression: validation and association with outcomes in the FIDELITY population Open

Tariq Shafi, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Luís M. Ruilope , et al. · 2024

Background and Aims The Chronic Kidney Disease Prognosis Consortium (CKD-PC) recently developed risk models to predict the 3-year risk of a ≥40% decrease in estimated glomerular filtration rate (eGFR) or to predict kidney failure in the ge…

Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population Open

Navdeep Tangri, Thomas W. Ferguson, Silvia J. Leon, Stefan D. Anker, Gerasimos Filippatos , et al. · 2024

Background Chronic kidney disease (CKD) affects >800 million individuals worldwide and is often underrecognized. Early detection, identification and treatment can delay disease progression. Klinrisk is a proprietary CKD progression risk…

Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials Open

Shweta Bansal, Maria Eugênia Fernandes Canziani, Rita Birne, Stefan D. Anker, George L. Bakris , et al. · 2024

Objectives This study aimed to evaluate the efficacy and safety of finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist, on cardiovascular and kidney outcomes by age and/or sex. Design FIDELITY post hoc analysis; me…

Effect of finerenone in patients with chronic kidney disease and type 2 diabetes by baseline anaemia status: a FIDELITY analysis Open

Ajay Singh, Stefan D. Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing , et al. · 2023

Introduction Anaemia is a common complication affecting ∼42% patients with chronic kidney disease (CKD) stages 3–5 at 1 year after diagnosis and ∼67% at 5 years, with prevalence increasing as estimated glomerular filtration rate (eGFR) dec…

Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials Open

John M. Flack, Rajiv Agarwal, Stefan D. Anker, Bertram Pitt, Luís M. Ruilope , et al. · 2023

FINERENONE IN CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES: A FIDELITY ANALYSIS OF LEFT VENTRICULAR HYPERTROPHY Open

Luis C. Matavelli, Gerasimos Filippatos, Stefan D. Anker, George L. Bakris, Peter Rossing , et al. · 2023

Therapeutic Area: Kidney Disease Background: Left ventricular hypertrophy (LVH) is a predictor of cardiovascular (CV) disease and associated morbidity and mortality. Patients with chronic kidney disease (CKD), type 2 diabetes (T2D) have a …

#4486 VALIDATION OF A CKD PROGRESSION RISK PREDICTION MODEL IN THE FIDELITY TRIAL POPULATION Open

Navdeep Tangri, Thomas W. Ferguson, Silvia Leon-Mantilla, Stefan D. Anker, Bertram Pitt , et al. · 2023

Background and Aims Chronic kidney disease (CKD) is often underrecognised until later stages when most of the kidney function is lost and the therapeutic window for disease-modifying therapy is narrow [1]. We previously developed a lab-bas…

IDF2022-1255 Efficacy and safety of finerenone by age and sex subgroups in patients with chronic kidney disease and type 2 diabetes Open

Saakshi Bansal, Stefan D. Anker, George L. Bakris, Gerasimos Filippatos, Peter Rossing , et al. · 2023

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score Open

Maria A. de Winter, Harry R. Büller, Marc Carrier, Alexander T. Cohen, John‐Bjarne Hansen , et al. · 2023

Aims Deciding to stop or continue anticoagulation for venous thromboembolism (VTE) after initial treatment is challenging, as individual risks of recurrence and bleeding are heterogeneous. The present study aimed to develop and externally …

36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE Open

Alexander G.G. Turpie, Alfredo E. Farjat, Sylvia Haas, Walter Ageno, Jeffrey I. Weitz , et al. · 2022

MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials Open

Marybeth A. Nedrud, Mohammad Rauf Chaudhry, Michael S. Middleton, Cynthia A. Moylan, Reginald Lerebours , et al. · 2022

Background Several early-phase clinical trials for the treatment of nonalcoholic steatohepatitis (NASH) use liver fat content as measured with the MRI-derived proton density fat fraction (PDFF) for a primary outcome. These trials have show…

Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease Open

Gerasimos Filippatos, Stefan D. Anker, Bertram Pitt, Darren K. McGuire, Peter Rossing , et al. · 2022

Aims Finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist, improves cardiovascular (CV) and kidney outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). This subgroup analysis of FIDELITY…

On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease Open

Sylvia Haas, Alfredo E. Farjat, Karen S. Pieper, Walter Ageno, Pantep Angchaisuksiri , et al. · 2022

Background Direct oral anticoagulants (DOACs) provide a safe, effective alternative to vitamin K antagonists (VKAs) for venous thromboembolism (VTE) treatment, as shown via intention-to-treat comparative effectiveness analysis. However, on…

36-Month Clinical Outcomes of Patients with Venous Thromboembolism: GARFIELD-VTE Open

Alexander G.G. Turpie, Alfredo E. Farjat, Sylvia Haas, Walter Ageno, J.I. Weitz , et al. · 2022

36-Month Clinical Outcomes of Patients with Venous Thromboembolism: GARFIELD-VTE Open

Alexander G.G. Turpie, Alfredo E. Farjat, Sylvia Haas, Walter Ageno, Jeffrey I. Weitz , et al. · 2022

Corrigendum to “Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE” [Thromb. Res. 2020 Jul; 191:103–112] Open

Henri Bounameaux, Sylvia Haas, Alfredo E. Farjat, Walter Ageno, Jeffrey I. Weitz , et al. · 2021

Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD‐VTE Open

Omri Cohen, Walter Ageno, Alfredo E. Farjat, Alexander G.G. Turpie, Jeffrey I. Weitz , et al. · 2021

The importance of the design of observational studies in comparative effectiveness research: Lessons from the GARFIELD-AF and ORBIT-AF registries Open

Alfredo E. Farjat, Saverio Virdone, Laine Thomas, Ajay K. Kakkar, Karen S. Pieper , et al. · 2021

Randomized controlled trials (RCTs) are considered the gold standard for estimating the effectiveness of a treatment. However, in many instances they are impractical to conduct because of time limitations, cost restrictions, or ethical rea…

The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE Open

Shinya Goto, Alexander G.G. Turpie, Alfredo E. Farjat, Jeffrey I. Weitz, Sylvia Haas , et al. · 2021

Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE Open

Walter Ageno, Alfredo E. Farjat, Sylvia Haas, Jeffrey I. Weitz, Samuel Z. Goldhaber , et al. · 2021

Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE Open

Carlos Jerjes‐Sánchez, David Rodríguez, Alfredo E. Farjat, Gloria Kayani, Peter MacCallum , et al. · 2021

Introduction The risk of venous thromboembolism (VTE) increases during pregnancy and the puerperium such that VTE is a leading cause of maternal mortality. Methods We describe the clinical characteristics, diagnostic strategies, treatment …

Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease Open

Shinya Goto, Sylvia Haas, Walter Ageno, Samuel Z. Goldhaber, Alexander G.G. Turpie , et al. · 2020

Importance: Patients with venous thromboembolism (VTE) and concomitant chronic kidney disease (CKD) have been reported to have a higher risk of thrombosis and major bleeding complications compared with patients without concomitant CKD. The…

Alfredo E. Farjat YOU? Author Swipe